Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. daily Stock Chart
Gilead Sciences, Inc.
IndexS&P 500 P/E6.90 EPS (ttm)9.94 Insider Own0.40% Shs Outstand1.30B Perf Week3.13%
Market Cap89.35B Forward P/E9.09 EPS next Y7.55 Insider Trans-10.84% Shs Float1.30B Perf Month2.21%
Income13.50B PEG- EPS next Q2.28 Inst Own78.00% Short Float0.98% Perf Quarter-2.97%
Sales30.39B P/S2.94 EPS this Y-16.50% Inst Trans0.05% Short Ratio1.31 Perf Half Y-6.53%
Book/sh14.36 P/B4.78 EPS next Y-8.57% ROA25.60% Target Price79.16 Perf Year-30.14%
Cash/sh9.19 P/C7.46 EPS next 5Y-4.70% ROE83.50% 52W Range64.88 - 98.19 Perf YTD-3.49%
Dividend2.08 P/FCF6.64 EPS past 5Y41.20% ROI31.00% 52W High-30.43% Beta1.18
Dividend %3.03% Quick Ratio2.00 Sales past 5Y29.40% Gross Margin86.00% 52W Low5.29% ATR0.83
Employees9000 Current Ratio2.20 Sales Q/Q-13.90% Oper. Margin58.00% RSI (14)58.73 Volatility1.42% 1.16%
OptionableYes Debt/Eq1.39 EPS Q/Q-26.40% Profit Margin44.40% Rel Volume0.60 Prev Close68.58
ShortableYes LT Debt/Eq1.39 EarningsMay 02 AMC Payout18.30% Avg Volume9.72M Price68.31
Recom2.30 SMA202.27% SMA500.61% SMA200-6.88% Volume2,262,663 Change-0.39%
Mar-09-17Resumed UBS Neutral $118 → $72
Feb-08-17Downgrade Citigroup Buy → Neutral
Nov-14-16Initiated Stifel Buy $100
Nov-08-16Initiated Mizuho Buy $88
Nov-02-16Reiterated RBC Capital Mkts Outperform $95 → $90
Oct-25-16Reiterated Jefferies Buy $93 → $95
Oct-03-16Reiterated RBC Capital Mkts Outperform $105 → $95
Sep-27-16Downgrade Leerink Partners Outperform → Mkt Perform $112 → $94
Sep-12-16Initiated Berenberg Buy $112
Sep-06-16Upgrade Jefferies Hold → Buy
Jul-29-16Downgrade Argus Buy → Hold
Jul-26-16Reiterated RBC Capital Mkts Outperform $120 → $105
Jul-26-16Downgrade Needham Buy → Hold
Jun-01-16Initiated Gabelli & Co Buy $109
Apr-29-16Reiterated UBS Buy $130 → $118
Apr-29-16Downgrade Maxim Group Buy → Hold
Mar-16-16Reiterated Leerink Partners Outperform $130 → $127
Feb-25-16Initiated Citigroup Buy $110
Feb-12-16Reiterated Maxim Group Buy $137 → $115
Feb-03-16Reiterated RBC Capital Mkts Outperform $130 → $120
Apr-28-17 08:55AM  Biotech Surge: How To Survive In A Volatile Market Investor's Business Daily
08:45AM  Why Gilead (GILD) Might Surprise This Earnings Season Zacks
07:04AM  Gilead earnings: Lowered expectations could help when company reports first-quarter results MarketWatch
Apr-27-17 05:16PM  Mixed bag for biotech earnings CNBC Videos
02:58PM  Gilead, NetApp, First Solar Could Profit Most on Trump's Tax Plan
10:41AM  1 Dividend Stock That Could Double Your Money Motley Fool
08:36AM  Gilead Sciences, Inc. breached its 50 day moving average in a Bullish Manner : GILD-US : April 27, 2017 Capital Cube
07:39AM  Biogen Reports Strong Revenue Growth in 1Q17 Market Realist
Apr-26-17 10:35AM  Gilead Sciences: Is the Bottom In?
08:18AM  Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug Zacks
Apr-25-17 04:00PM  Gilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates? Zacks
01:39PM  Gilead Sciences: NASH BridgesTo What?
08:43AM  3 Stocks Could Double Their Dividends -- But Shouldn't Motley Fool
06:05AM  America's 12 Most Charitable Companies Motley Fool
Apr-24-17 01:02PM  Better Buy: Gilead Sciences vs. Celgene Motley Fool
11:22AM  Gilead Sciences: Know Hopeor No Hope?
10:06AM  Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1? Zacks
Apr-23-17 01:07PM  11 Most Profitable Companies In The Fortune 500 Insider Monkey
11:41AM  Should Gilead Sciences Be Worried About Allergan? Motley Fool
Apr-22-17 02:12PM  Why Now Is Not the Time to Buy Valeant Pharmaceuticals Motley Fool
Apr-21-17 01:46PM  Gilead Sciences: Just Like Thermopylae?
12:02PM  Should Gilead Sciences Acquire NewLink Genetics? Motley Fool
12:00PM  Gilead Announces Scientific Presentations Demonstrating Efficacy of Harvoni® (Ledipasvir/Sofosbuvir) in Special Patient Populations With HCV Infection Business Wire
08:08AM  10 Reasons Merck Could Be the World's Most Perfect Stock Motley Fool
07:49AM  3 Reasons Gilead Sciences Is a Better Dividend Stock Than Johnson & Johnson Motley Fool
04:30AM  Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress 2017 Business Wire
Apr-20-17 12:00PM  Gilead Presents Data at the International Liver Congress 2017 Supporting the Efficacy and Safety of Vemlidy in Patients with Chronic Hepatitis B After 96 Weeks, and Also After Switching From Viread Business Wire
09:30AM  Gilead to Present Clinical and Preclinical Data on Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress 2017 Business Wire
Apr-19-17 11:42AM  Gilead Sciences: Who's Frustrated Now?
08:04AM  Looking for a Smart Way to Use Your Tax Refund? Buy These 3 Stocks Motley Fool
Apr-18-17 05:00PM  Gilead Sciences to Release First Quarter 2017 Financial Results on Tuesday, May 2, 2017 Business Wire
01:34PM  The Better Big Pharma Stock: AbbVie or Gilead?
09:01AM  Here's The Real Reason Gilead Sciences Is So Incredibly Cheap Motley Fool
Apr-17-17 10:51AM  Gilead, Pfizer, AbbVie Win From Lilly's Loss
08:57AM  FDA Complete Response Smacks LLY & INCY, What Now? Investopedia
Apr-16-17 05:02PM  Stocks That Fell to 3-Year Lows in the Week of April 14
11:01AM  Why Gilead Sciences Could Be a Gold Mine for Value Investors Motley Fool
Apr-15-17 12:02PM  3 Biotech Stocks to Buy on Sale Motley Fool
Apr-13-17 04:18PM  The Hot Stock: Alexion Pharmaceuticals Climbs 3.3%
Apr-12-17 01:59PM  Biotech ETFs To Consider Ahead of Earnings Season
12:51PM  How These Biotechs Could Save The Drug Sector In Q1 Or Not Investor's Business Daily
11:25AM  [$$] Celgene, Biogen to Gain From Higher Prices
06:00AM  First Quarter Earnings Preview: Biotech Heavyweights Investopedia
Apr-11-17 03:03PM  3 Big Drugmakers Most Likely to Buy Incyte Motley Fool
08:20AM  3 Fire-Sale Stocks: Will They Bounce Back or Burn You? Motley Fool
Apr-10-17 05:27PM  Gilead (GILD) HCV Drugs Gets FDA Nod for Label Expansion Zacks
10:53AM  Does Incyte Have The Best Cancer Portfolio Among Mid-Cap Biotechs?
09:06AM  Examining Gilead Sciences 1Q17 Performance Market Realist
01:00AM  Takeaways and Observations; Play a Tesla Tune: Doug Kass' Views
Apr-09-17 03:03PM  The 3 Best HIV Drug Stocks to Buy in 2017 Motley Fool
Apr-08-17 12:01AM  [$$] Celgene Outlook Brightens, While Gilead Faces Woes
Apr-07-17 04:16PM  Gilead Hepatitis C Drugs Get Supplemental FDA Nod Investopedia
02:43PM  Would Gilead Sciences Make This Staggeringly Audacious Move? Motley Fool
01:34PM  Why Roche's New Drug Is Bad News For Biogen
10:11AM  U.S. FDA Approves New Indications for Harvoni® and Sovaldi® in Pediatric Patients 12 Years and Older with Chronic Hepatitis C Infection Business Wire
07:30AM  Today's Research Reports on Top Biotech Stocks: Gilead Sciences and Celgene Accesswire
Apr-06-17 04:55PM  Will Gilead's HIV Franchise Plan Be Dashed On TrumpCare? Investor's Business Daily
03:32PM  3 Stocks to Buy Near 52-Week Lows Motley Fool
11:42AM  Gilead Sciences: Another Reason to Worry?
10:47AM  Gilead Sciences, Inc. : GILD-US: Dividend Analysis : March 16th, 2017 (record date) : By the numbers : April 6, 2017 Capital Cube
10:21AM  Gilead Sciences: The Bull, the Bear and the Fence-Sitter Motley Fool
09:30AM  KMG Chemicals, Gilead Sciences, STMicroelectronics NV, Lockheed Martin and AeroVironment highlighted as Zacks Bull and Bear of the Day Zacks
07:15AM  Bear of the Day: Gilead Sciences (GILD) Zacks
05:00AM  Just How Much Is a Medical Miracle Worth? Bloomberg
Apr-05-17 07:40AM  Gilead (GILD) Up 4.3% Since Earnings Report: Can It Continue? Zacks
Apr-04-17 04:55PM  Galapagos Initiates 3 Phase II Studies for Filgotinib Zacks
Apr-03-17 01:02PM  6 Reasons Gilead Sciences Could Be the World's Most Perfect Stock Motley Fool
11:11AM  3 Lowest P/E Stocks Today Motley Fool
11:10AM  Alberta Lists EPCLUSA on Public Drug Plan to Treat All Six Genotypes of Chronic Hepatitis C Infection CNW Group
Apr-01-17 06:41AM  The Worst-Case Scenario for Gilead Sciences, Inc. Motley Fool
Mar-31-17 10:37AM  New Strong Sell Stocks for March 31st Zacks
09:43AM  Can Vertex Keep Climbing?
Mar-30-17 11:00AM  Here's What You Missed On PreMarket Prep Today Benzinga
10:41AM  Has Gilead Sciences Lost Its Way? at Motley Fool
08:46AM  Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst'
Mar-29-17 03:42PM  3 Drugmakers With Boatloads of Cash to Spend at Motley Fool
08:15AM  Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study
Mar-28-17 01:49PM  These 2 Stocks Are Ridiculously Cheap at Motley Fool
12:28PM  Rahul Garg Says Trump's Tweets About Drug Prices Have Made Gilead A Buy at Forbes
07:23AM  3 Least Risky Biotech Stocks on the Market at Motley Fool
Mar-27-17 10:30AM  Short Interest Pulls Back in Major Biotechs
09:51AM  Gileads Hep C Bestseller Faces Patent Dispute (GILD) at Investopedia
09:46AM  Better Buy: Celgene Corporation vs. Gilead Sciences at Motley Fool
07:47AM  3 Top Dividend Stocks Selling for a Discount This Spring at Motley Fool
04:28AM  Gilead hepatitis C drug patent faces European challenge Reuters
01:00AM  Alphabet, Allergan, Ford: Doug Kass' Views
Mar-24-17 08:04AM  The Best-Case Scenario for Gilead Sciences, Inc. at Motley Fool
Mar-23-17 10:57AM  Biotechs Back in the Doghouse After Failed Rally at Investopedia
Mar-22-17 04:23PM  My 3 Worst-Performing Stocks -- and Why I Still Own Them at Motley Fool
09:30AM  Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen
Mar-21-17 04:22PM  Mylan Receives Tentative Approval from FDA for HIV Therapy
04:00PM  British Columbia lists EPCLUSA on public drug plan to treat all six genotypes of chronic hepatitis C infection CNW Group
08:52AM  Ionis Pharmaceuticals Valuation Compared to Its Peers
Mar-20-17 04:22PM  3 Stocks That Are Ridiculously Cheap Right Now at Motley Fool
01:08PM  Gilead Sciences: Wait, Its Pipeline Isn't Completely Barren? at
12:25PM  EPCLUSA, to treat all six genotypes of chronic hepatitis C infection, added to the Liste des médicaments de la RAMQ CNW Group
10:06AM  Why Biotech Stock Gilead (GILD) Could Be a Value Trap
09:50AM  Jefferies Has 4 Red-Hot Biotech and Pharmaceutical Stocks to Buy Now
Mar-17-17 11:03AM  3 Drug Stocks With Some of the Highest Profit Margins at Motley Fool
Mar-16-17 03:40PM  3 Numbers That Make Gilead Sciences, Inc. Look Cheaper Than It Really Is at Motley Fool
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN JOHN CExecutive ChairmanApr 03Option Exercise21.5873,3331,582,1593,199,969Apr 05 05:29 PM
MARTIN JOHN CExecutive ChairmanApr 03Sale67.1873,3334,926,2873,126,636Apr 05 05:29 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMar 30Sale67.485,000337,392117,988Apr 03 06:23 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise21.5873,3331,582,1593,199,969Mar 03 06:29 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00173012,055Mar 03 06:03 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale70.3873,3335,161,2063,126,636Mar 03 06:29 PM
WILSON GAYLE EDirectorFeb 23Option Exercise20.7133,350690,512140,836Feb 27 06:29 PM
MILLIGAN JOHN FPresident and CEOFeb 23Option Exercise21.58100,0002,157,5001,165,924Feb 27 06:13 PM
WILSON GAYLE EDirectorFeb 23Sale69.3020,3651,411,374120,471Feb 27 06:29 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.0090802,883Feb 14 12:53 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise21.5873,3331,582,1593,204,429Feb 03 05:25 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.0062002,190Feb 03 05:32 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale72.5773,3335,322,0693,131,096Feb 03 05:25 PM
MARTIN JOHN CExecutive ChairmanJan 03Option Exercise21.5873,3371,582,2463,204,433Jan 05 03:39 PM
MARTIN JOHN CExecutive ChairmanJan 03Sale73.5973,3375,396,9713,131,096Jan 05 03:39 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise16.40100,0001,639,5003,231,096Dec 05 12:54 PM
WILSON GAYLE EDirectorDec 01Option Exercise0.002,1470107,486Dec 05 07:59 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale73.33100,0007,332,8703,131,096Dec 05 12:54 PM
MADIGAN JOHN WDirectorNov 18Option Exercise20.71105,0002,174,025121,761Nov 22 02:45 PM
MADIGAN JOHN WDirectorNov 18Sale74.86105,0007,860,05916,761Nov 22 02:45 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 09Sale79.0010,000790,000122,964Nov 14 01:03 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise16.40100,0001,639,5003,231,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale73.76100,0007,376,0463,131,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanOct 03Option Exercise16.40100,0001,639,5003,231,096Oct 05 12:52 PM
MARTIN JOHN CExecutive ChairmanOct 03Sale77.63100,0007,762,9613,131,096Oct 05 12:52 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 22Sale81.845,000409,220132,964Sep 26 04:54 PM
MILLIGAN JOHN FPresident and CEOSep 06Option Exercise20.7470,0001,451,8001,128,963Sep 08 01:35 PM
MILLIGAN JOHN FPresident and CEOSep 06Sale77.7470,0005,442,0801,058,963Sep 08 01:35 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise16.40100,0001,639,5003,231,096Sep 06 02:40 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale77.48100,0007,748,3633,131,096Sep 06 02:40 PM
Lofton Kevin EDirectorAug 24Sale81.973,500286,8990Aug 25 05:05 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise39.132,00078,25564,305Aug 03 04:48 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise16.40100,0001,639,5004,119,727Aug 03 04:51 PM
MILLIGAN JOHN FPresident and CEOAug 01Option Exercise20.7470,0001,451,8001,128,963Aug 03 04:53 PM
MILLIGAN JOHN FPresident and CEOAug 01Sale70.9470,0004,965,5901,058,963Aug 03 04:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale80.50100,0008,049,7854,019,727Aug 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Sale79.812,000159,62062,305Aug 03 04:48 PM
Carter Paul RutherfordEVP Commercial OpsJul 31Option Exercise0.002,500063,622Aug 02 04:43 PM
MILLIGAN JOHN FPresident and CEOJul 05Option Exercise16.40112,0001,836,2401,170,963Jul 07 02:50 PM
MILLIGAN JOHN FPresident and CEOJul 05Sale84.33112,0009,444,9211,058,963Jul 07 02:50 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Option Exercise24.912,00049,81063,122Jul 06 01:26 PM
MARTIN JOHN CExecutive ChairmanJul 01Option Exercise16.40100,0001,639,5004,119,727Jul 06 01:28 PM
MARTIN JOHN CExecutive ChairmanJul 01Sale84.73100,0008,472,5234,019,727Jul 06 01:28 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Sale83.122,000166,25061,122Jul 06 01:26 PM
MILLIGAN JOHN FPresident and CEOJun 06Option Exercise16.40112,0001,836,2401,170,963Jun 08 06:59 PM
MILLIGAN JOHN FPresident and CEOJun 06Sale86.94112,0009,736,7791,058,963Jun 08 06:59 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Option Exercise24.912,00049,81063,122Jun 03 04:46 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise16.40100,0001,639,5004,119,727Jun 03 04:51 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale86.72100,0008,671,9504,019,727Jun 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Sale87.022,000174,04061,122Jun 03 04:46 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Option Exercise33.8857,0921,934,021118,214Jun 02 04:35 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Sale86.8557,0924,958,60061,122Jun 02 04:35 PM
MARTIN JOHN CExecutive ChairmanMay 02Option Exercise16.40100,0001,639,5004,119,727May 04 02:44 PM
MILLIGAN JOHN FPresident and CEOMay 02Option Exercise16.40112,0001,836,2401,170,963May 04 02:49 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Option Exercise39.132,00078,25563,122May 04 04:23 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Sale88.722,000177,44861,122May 04 04:23 PM
MILLIGAN JOHN FPresident and CEOMay 02Sale87.71112,0009,823,9541,058,963May 04 02:49 PM
MARTIN JOHN CExecutive ChairmanMay 02Sale87.82100,0008,781,6944,019,727May 04 02:44 PM